<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="41503">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02566083</url>
  </required_header>
  <id_info>
    <org_study_id>TIOL-202-TPAS</org_study_id>
    <nct_id>NCT02566083</nct_id>
  </id_info>
  <brief_title>Post-Approval Study of the Tecnis® Toric IOL</brief_title>
  <official_title>Post-Approval Study of the Tecnis® Toric IOL, Models ZCT300 and ZCT400</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott Medical Optics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abbott Medical Optics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Post-approval study to evaluate the rates of visual distortions for patients requiring &gt;2.0
      D of corneal astigmatism correction
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2015</start_date>
  <completion_date type="Anticipated">August 2018</completion_date>
  <primary_completion_date type="Anticipated">February 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of severe visual distortions</measure>
    <time_frame>6 Months</time_frame>
    <description>Rate of visual distortions based on data collected from a self-administered subject questionnaire</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of IOL repositioning procedures due to IOL misalignment</measure>
    <time_frame>1 Year</time_frame>
    <description>repositioning due to intraocular lens (IOL) mis-alignment</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Rate of other adverse events</measure>
    <time_frame>1 Year</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">435</enrollment>
  <condition>Cataract</condition>
  <arm_group>
    <arm_group_label>non-toric intraocular lens</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>non-toric approved intraocular lens</description>
  </arm_group>
  <arm_group>
    <arm_group_label>toric intraocular lens</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>approved toric intraocular lens</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>non-toric intraocular lens</intervention_name>
    <description>TECNIS One-piece Monofocal Model ZCB00</description>
    <arm_group_label>non-toric intraocular lens</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>toric intraocular lens</intervention_name>
    <description>TECNIS One-piece Toric Models ZCT300 or ZCT400</description>
    <arm_group_label>toric intraocular lens</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Minimum 22 years of age

          -  Bilateral cataracts

          -  Preoperative keratometric cylinder in both eyes

          -  Most appropriate toric IOL model choice (ZCT300 or ZCT400)

          -  Predicted residual refractive cylinder, based on the AMO Toric IOL Calculator, must
             be:

             ≤ 0.69 D for a ZCT300 IOL or ≤ 0.88 D for a ZCT400 IOL

          -  Clear intraocular media other than cataract in each eye

          -  Availability, willingness, ability and sufficient cognitive awareness to comply with
             examination procedures and study visits

          -  Ability to understand, read and write English in order to consent to study
             participation and complete a study questionnaire

          -  Signed informed consent and HIPAA authorization

        Exclusion Criteria:

          -  Irregular corneal astigmatism

          -  Any corneal pathology/abnormality other than regular corneal astigmatism

          -  Previous corneal surgery

          -  Recent ocular trauma or intraocular surgery that is not resolved/stable or may affect
             visual outcomes

          -  Any pupil abnormalities

          -  Subjects with conditions associated with increased risk of zonular rupture, including
             capsular or zonular abnormalities that may lead to IOL decentration, including
             pseudoexfoliation, trauma, or posterior capsule defects

          -  Known ocular disease or pathology that may affect visual acuity or that may require
             surgical intervention during the course of the study

          -  Concurrent participation or participation during 30 days prior to preoperative visit
             in any other clinical study

          -  Planned monovision correction

          -  Patient is pregnant, plans to become pregnant, is lactating or has another condition
             associated with the fluctuation of hormones that could lead to refractive changes
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>22 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Rosangela Nolasco, DMD, MPH</last_name>
    <phone>714-247-8624</phone>
    <email>rosangela.nolasco@abbott.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Carrie Garufis</last_name>
    <phone>714-566-3728</phone>
    <email>carrie.garufis@abbott.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Empire Eye &amp; Laser Center</name>
      <address>
        <city>Bakersfield</city>
        <state>California</state>
        <zip>93309</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jacque Whinery</last_name>
      <phone>661-432-7204</phone>
      <email>jwhinery@empireeyandlaser.com</email>
    </contact>
    <contact_backup>
      <last_name>Dana Blake</last_name>
      <phone>661-325-3937</phone>
      <email>dblake@empireeyeandlaser.com</email>
    </contact_backup>
    <investigator>
      <last_name>Daniel Chang, M.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2016</verification_date>
  <lastchanged_date>June 1, 2016</lastchanged_date>
  <firstreceived_date>September 30, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cataract</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
